Get the Stockscreener App
3.58
2.72%
-0.10
After Hours:
3.56
-0.02
-0.56%
Ironwood Pharmaceuticals Inc stock is traded at $3.58, with a volume of 1.53M.
It is down -2.72% in the last 24 hours and up +15.11% over the past month.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
See More
Previous Close:
$3.68
Open:
$3.68
24h Volume:
1.53M
Relative Volume:
0.74
Market Cap:
$582.39M
Revenue:
$400.57M
Net Income/Loss:
$9.21M
P/E Ratio:
89.50
EPS:
0.04
Net Cash Flow:
$146.36M
1W Performance:
+2.87%
1M Performance:
+15.11%
6M Performance:
+435.61%
1Y Performance:
+0.56%
1-Day Range:
$3.53
$3.68
1-Week Range:
$3.22
$3.85
52-Week Range:
$0.5271
$5.1288
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.58 | 598.66M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Up 6%What's Next? - MarketBeat
Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report? - Yahoo Finance
Can Ironwood Pharmaceuticals Stock Recover If Markets Fall? - Trefis
Ironwood Pharmaceuticals (IRWD) Price Target Increased by 38.89% to 2.55 - Nasdaq
Can Ironwood Pharmaceuticals Stock Hold Up When Markets Turn? - Trefis
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 5%Time to Sell? - MarketBeat
Is Ironwood Pharmaceuticals Inc. (I76) stock cheap by valuation metricsOptions Play & Scalable Portfolio Growth Ideas - Newser
Can Ironwood Pharmaceuticals Inc. stock sustain institutional interestProfit Target & Fast Gaining Stock Strategy Reports - Newser
Zacks Research Analysts Increase Earnings Estimates for IRWD - MarketBeat
Why Ironwood Pharmaceuticals Inc. (I76) stock could be next leaderJuly 2025 Macro Moves & Community Verified Swing Trade Signals - Newser
How dovish Fed policy supports Ironwood Pharmaceuticals Inc. (I76) stockRecession Risk & Weekly High Return Forecasts - Newser
Irritable Bowel Syndrome (IBS) Treatment Market Competition Analysis 2025: How Players Are Shaping Growth - EIN News
IRWD SEC FilingsIronwood 10-K, 10-Q, 8-K Forms - Stock Titan
Is Ironwood Pharmaceuticals, Inc. overvalued or undervalued? - Markets Mojo
How Ironwood Pharmaceuticals Inc. (I76) stock trades under stagflationLayoff News & Fast Momentum Entry Tips - Newser
Volume Summary: Can Ironwood Pharmaceuticals Inc stock deliver 10 annual returns2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - BỘ NỘI VỤ
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading 4.5% HigherTime to Buy? - MarketBeat
Ironwood Pharmaceuticals (IRWD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Universal Beteiligungs und Servicegesellschaft mbH Buys 108,822 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
What Catalysts Are Shaping the Changing Narrative for Ironwood Pharmaceuticals? - Yahoo Finance
Ironwood (IRWD) Skyrockets 23% as Govt Price for Linzess Falls Within Expectations - Finviz
Ironwood Pharma’s LINZESS® Price Set by HHS - MSN
Ironwood Pharmaceuticals chief legal officer sells shares worth $68,530 - MSN
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick? - sharewise.com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap UpHere's Why - MarketBeat
Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous H1 2025 (IRWD) - Seeking Alpha
Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On WednesdayArrowhead Pharma (NASDAQ:ARWR), Duolingo (NASDAQ:DUOL) - Benzinga
Ironwood Pharmaceuticals IncHHS releases maximum fair price for LinzessSEC filing - marketscreener.com
IRONWOOD PHARMACEUTICALS INC Announces LINZESS Price Update - TradingView
IRWD: LINZESS Medicare net price to be $136 from 2027 - Stock Titan
Ironwood Pharmaceuticals (IRWD) Q3 Earnings and Revenues Surpass Estimates - MSN
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3? - sharewise.com
How Ironwood Pharmaceuticals Inc. (I76) stock moves on employment data2025 Market Overview & Comprehensive Market Scan Insights - newser.com
Will Ironwood Pharmaceuticals Inc. stock outperform Dow Jones indexMarket Activity Report & Smart Swing Trading Techniques - newser.com
Published on: 2025-11-21 02:18:04 - newser.com
How Ironwood Pharmaceuticals Inc. stock benefits from strong dollarJuly 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
Is Ironwood Pharmaceuticals Inc. (I76) stock attractive for dividend growthJuly 2025 Review & Capital Protection Trading Alerts - newser.com
How Ironwood Pharmaceuticals Inc. stock compares to industry benchmarksWeekly Trade Recap & Low Risk Profit Maximizing Plans - newser.com
Is Ironwood Pharmaceuticals Inc. stock a dividend growth opportunityMarket Growth Report & Smart Allocation Stock Tips - newser.com
VP Gaskins Surrenders 6,016 Of Ironwood Pharmaceuticals Inc [IRWD] - TradingView
[Form 4] IRONWOOD PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Can Ironwood Pharmaceuticals Inc. (I76) stock deliver strong annual returnsWeekly Volume Report & AI Forecast for Swing Trade Picks - newser.com
Can Ironwood Pharmaceuticals Inc. stock deliver strong Q4 earningsMarket Sentiment Summary & Fast Moving Stock Trade Plans - newser.com
Will earnings trigger a reversal in Ironwood Pharmaceuticals Inc.2025 Price Momentum & AI Enhanced Trading Signals - newser.com
Will breakout in Ironwood Pharmaceuticals Inc. lead to full recoveryMarket Activity Report & Real-Time Market Trend Scan - newser.com
Can Ironwood Pharmaceuticals Inc. stock continue upward trendDip Buying & Intraday High Probability Setup Alerts - newser.com
Price momentum metrics for Ironwood Pharmaceuticals Inc. explainedQuarterly Portfolio Report & Safe Investment Capital Preservation Plans - newser.com
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):